TY - JOUR
T1 - Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma
T2 - A phase ii study
AU - Zustovich, Fable
AU - Landi, Lorenza
AU - Lombardi, Giuseppe
AU - Porta, Camillo
AU - Galli, Luca
AU - Fontana, Andrea
AU - Amoroso, Domenico
AU - Galli, Costanza
AU - Andreuccetti, Michele
AU - Falcone, Alfredo
AU - Zagonel, Vittorina
PY - 2013/8
Y1 - 2013/8
N2 - Background: Bevacizumab has provided encouraging results in relapsed glioblastoma multiforme (GBM). Pre-clinical and clinical investigations also showed that continuous low-dose temozolomide has some antiangiogenic activity. Based on this evidence, a phase II trial was designed to investigate an oral regimen of sorafenib, an oral multikinase inhibitor, and metronomic temozolomide for relapsed GBM. Patients and Methods: Forty-three patients (median age=60.0 years) naive for antiangiogenic agents received 400 mg sorafenib twice daily plus TMZ 40 mg/m2/day until disease progression. Results: Toxicity, mostly grade 1-2, was manageable. Grade 3-4 toxicities were hand-foot syndrome (n=4), hypertension (n=2), and fatigue (n=3). Five patients (12%) achieved partial response, 18 (43%) stable disease, 20 (48%) showed progression. The median time-to-progression was 3.2 months, 6-month progression-free survival was 26%, and median overall survival was 7.4 months. Conclusion: This combination of sorafenib and temozolomide was feasible and safe, showing some activity in patients with relapsed GBM.
AB - Background: Bevacizumab has provided encouraging results in relapsed glioblastoma multiforme (GBM). Pre-clinical and clinical investigations also showed that continuous low-dose temozolomide has some antiangiogenic activity. Based on this evidence, a phase II trial was designed to investigate an oral regimen of sorafenib, an oral multikinase inhibitor, and metronomic temozolomide for relapsed GBM. Patients and Methods: Forty-three patients (median age=60.0 years) naive for antiangiogenic agents received 400 mg sorafenib twice daily plus TMZ 40 mg/m2/day until disease progression. Results: Toxicity, mostly grade 1-2, was manageable. Grade 3-4 toxicities were hand-foot syndrome (n=4), hypertension (n=2), and fatigue (n=3). Five patients (12%) achieved partial response, 18 (43%) stable disease, 20 (48%) showed progression. The median time-to-progression was 3.2 months, 6-month progression-free survival was 26%, and median overall survival was 7.4 months. Conclusion: This combination of sorafenib and temozolomide was feasible and safe, showing some activity in patients with relapsed GBM.
KW - Chemotherapy
KW - Glioblastoma
KW - Relapse
KW - Sorafenib
KW - Temozolomide
UR - http://www.scopus.com/inward/record.url?scp=84883261716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883261716&partnerID=8YFLogxK
M3 - Article
C2 - 23898124
AN - SCOPUS:84883261716
VL - 33
SP - 3487
EP - 3494
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 8
ER -